Impact of Levodopa vs. Rotigotine on stress hormones and NGF in patients with Parkinson's Disease: A randomised, placebo-controlled double-blind trial.

Trial Profile

Impact of Levodopa vs. Rotigotine on stress hormones and NGF in patients with Parkinson's Disease: A randomised, placebo-controlled double-blind trial.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 23 Mar 2012

At a glance

  • Drugs Levodopa/carbidopa; Rotigotine
  • Indications Restless legs syndrome
  • Focus Pharmacokinetics
  • Sponsors Schwarz BioSciences
  • Most Recent Events

    • 30 May 2011 Planned number of patients changed to 24.
    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top